Eton Pharmaceuticals price target raised to $10 from $8 at Craig-Hallum

Craig-Hallum raised the firm’s price target on Eton Pharmaceuticals (ETON) to $10 from $8 and keeps a Buy rating on the shares following Eton’s acquisition of pediatric endocrinology drug Increlex from Ipsen (IPSEY). The firm says this move will be highly accretive to the company, and thinks it adds $10M in EBITDA in 2025 at current Increlex revenue levels of $19M, the analyst tells investors in a research note.